TNFRSF12A and cancer: Our previous study found that tumoral Fn14 is an attractive target for treating cancer cachexia, and antagonistic anti-Fn14 monoclonal antibodies have shown a potent effect on ameliorating cancer cachexia in different preclinical models [7], which was also validated in this study.